Relmada Therapeutics, Inc. (RLMD)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20267 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Relmada Therapeutics, Inc.’s names, not what it holds today.
5 published
2 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Mar 21, 2023 | 11,607,407 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | Pharmaceuticals | Relmada Therapeutics, Inc. |
| Apr 21, 2020 | 10,624,887 | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol | Pharmaceuticals | Relmada Therapeutics, Inc. |
| Jan 2, 2018 | 9,855,226 | d-methadone for the treatment of psychiatric symptoms | Pharmaceuticals | Relmada Therapeutics, Inc. |
| Oct 18, 2016 | 9,468,611 | d-Methadone for the treatment of psychiatric symptoms | Pharmaceuticals | Relmada Therapeutics, Inc. |
| Jun 14, 2016 | 9,364,430 | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol | Pharmaceuticals | Relmada Therapeutics, Inc. |
| Sep 8, 2015 | 9,125,833 | Multimodal abuse resistant and extended release opioid formulations | Pharmaceuticals | Relmada Therapeutics, Inc. |
| Dec 11, 2012 | 8,329,744 | Methods of preventing the serotonin syndrome and compositions for use thereof | Pharmaceuticals | Relmada Therapeutics, Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.